# Study of the Effect of GS-6615 in Subjects With LQT-3

> **NCT01849003** · PHASE1 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 24 (actual)

## Conditions studied

- Long QT Syndrome

## Interventions

- **DRUG:** GS-6615

## Key facts

- **NCT ID:** NCT01849003
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01849003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01849003, "Study of the Effect of GS-6615 in Subjects With LQT-3". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01849003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*